| Symbol | ABOS |
|---|---|
| Name | ACUMEN PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 427 PARK STREET, CHARLOTTESVILLE, Virginia, 22902, United States |
| Telephone | +1 434 297-1000 |
| Fax | — |
| — | |
| Website | https://www.acumenpharm.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001576885 |
| Description | Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimers disease. The companys lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Additional info from NASDAQ: |
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Read moreDirector Porter Derrell 🟡 adjusted position in 32.3K shares (2 derivative) of Acumen Pharmaceuticals, Inc. (ABOS) at $2.35 Transaction Date: Jun 15, 2026 | Filing ID: 043987
Read more📋 DERRELL PORTER (Director) plans to sell 13K shares of ACUMEN PHARMACEUTICALS, INC. (at $2.33 each, total $30K) Filed: Jun 17, 2026 | ID: 006245
Read more📋 DERRELL PORTER (Director) plans to sell 13K shares of ACUMEN PHARMACEUTICALS, INC. (at $2.33 each, total $30K) Filed: Jun 16, 2026 | ID: 006235
Read more(91% Neutral) ACUMEN PHARMACEUTICALS, INC. (ABOS) Provides Update on submission for a stable
Read moreAcumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
Read more📋 DERRELL PORTER (Director) plans to sell 6K shares of ACUMEN PHARMACEUTICALS, INC. (at $2.35 each, total $15K) Filed: Jun 15, 2026 | ID: 006161
Read moreDirector Fountain Nathan B 🔴 sold 6.4K shares of Acumen Pharmaceuticals, Inc. (ABOS) at $2.23 Transaction Date: Jun 09, 2026 | Filing ID: 042280
Read more📋 NATHAN FOUNTAIN (Director) plans to sell 6K shares of ACUMEN PHARMACEUTICALS, INC. (at $2.23 each, total $14K) Filed: Jun 09, 2026 | ID: 005810
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 88.8K shares (1 derivative) of Acumen Pharmaceuticals, Inc. (ABOS) at $2.29 Transaction Date: Jun 03, 2026 | Filing ID: 000604
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonis… | Phase1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Not_Yet_Recruiting | 2026-08-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonis… | Phase1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Not_Yet_Recruiting | 2026-08-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT06511570 | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug … | Phase1 | Alzheimer Disease | Completed | 2024-06-25 | 2024-09-17 | ClinicalTrials.gov |
| NCT06511570 | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug … | Phase1 | Alzheimer Disease | Completed | 2024-06-25 | 2024-09-17 | ClinicalTrials.gov |
| NCT06335173 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participan… | Phase2 | Alzheimer Disease | Active_Not_Recruiting | 2024-02-29 | 2026-10-01 | ClinicalTrials.gov |
| NCT06335173 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participan… | Phase2 | Alzheimer Disease | Active_Not_Recruiting | 2024-02-29 | 2026-10-01 | ClinicalTrials.gov |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With … | Phase1 | Fibrolamellar Hepatocellular Carcinoma | Recruiting | 2024-02-12 | 2033-09-01 | ClinicalTrials.gov |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With … | Phase1 | Fibrolamellar Hepatocellular Carcinoma | Recruiting | 2024-02-12 | 2033-09-01 | ClinicalTrials.gov |
| NCT04931459 | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Par… | Phase1 | Alzheimer Disease | Completed | 2021-06-21 | 2023-06-12 | ClinicalTrials.gov |
| NCT04931459 | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Par… | Phase1 | Alzheimer Disease | Completed | 2021-06-21 | 2023-06-12 | ClinicalTrials.gov |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2020-08-31 | 2023-03-28 | ClinicalTrials.gov |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2020-08-31 | 2023-03-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Ipilimumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DNAJB1-PRKACA Peptide Vaccine | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Ipilimumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DNAJB1-PRKACA Peptide Vaccine | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| atezolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| DRP-104 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| DRP-104 | Other | Phase PHASE1 | Fibrolamellar Hepatocellular Carcinoma | RECRUITING | NCT06027086 |
| Durvalumab | Other | Phase PHASE1 | Fibrolamellar Hepatocellular Carcinoma | RECRUITING | NCT06027086 |
| Ipilimumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DNAJB1-PRKACA Peptide Vaccine | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Ipilimumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DNAJB1-PRKACA Peptide Vaccine | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Ipilimumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DNAJB1-PRKACA Peptide Vaccine | Other | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04931459 |
| ACU193 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04931459 |
| Sabirnetug + rHuPH20 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT06511570 |
| sabirnetug (ACU193) | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT06511570 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT06335173 |
| sabirnetug | Other | Phase PHASE2 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT06335173 |
| Diclofenac | DRUG | Phase PHASE3 | Osteo Arthritis of the Knee | COMPLETED | NCT01456611 |
| Lubiprostone | DRUG | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01372423 |
| atezolizumab | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| Placebo oral capsule | DRUG | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03265288 |
| LAU-7b | DRUG | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03265288 |
| Placebo for 3 cycles | OTHER | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| LAU-7b for 1 cycle, then placebo | DRUG | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| LAU-7b for 3 cycles | DRUG | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| Durvalumab | DRUG | Phase PHASE1 | Fibrolamellar Hepatocellular Carcinoma | RECRUITING | NCT06027086 |
| Ipilimumab | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| DNAJB1-PRKACA Peptide Vaccine | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Placebo | DRUG | Phase PHASE3 | Osteo Arthritis of the Knee | COMPLETED | NCT01456611 |